CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders |
ChemoCentryx, Inc. (the Company) held its annual meeting of
stockholders on May25, 2017. The following is a brief description
of each matter voted upon at the meeting and the number of votes
cast for, withheld or against, the number of abstentions and the
number of broker non-votes with respect to each matter, as
applicable.
| 1. |
To elect the following directors for a three-year term to expire at the 2020 annual meeting of stockholders: |
|
Director Name |
For | Withheld | BrokerNon-Votes | |||||||||
|
Thomas A. Edwards |
36,448,179 | 157,783 | 4,699,157 | |||||||||
|
Roger C. Lucas, Ph.D. |
36,098,103 | 507,859 | 4,699,157 |
In accordance with the above results, above nominees were elected
to serve as directors.
| 2. |
To ratify the selection of Ernst Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017: |
|
For |
Against | Abstain | BrokerNon-Votes | |||||||||
|
41,276,359 |
25,163 | 3,597 |
In accordance with the above results, the selection of Ernst and
Young LLP was approved.
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases. CHEMOCENTRYX, INC. (NASDAQ:CCXI) Recent Trading Information
CHEMOCENTRYX, INC. (NASDAQ:CCXI) closed its last trading session up +0.02 at 6.97 with 61,731 shares trading hands.
